Vantage logo

Astra aims for “the Trump setting”

Pivotal trials of Astrazeneca's Covid-19 antibody get under way, with hopes that a longer half-life and more convenient dosing will set the project apart.

Vantage logo

Novo adds weight to its obesity goals

Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.

Vantage logo

Zynerba hopes to crack fragile X at last

The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.